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Introductory Chapter: 
Introduction to Novel Aspects on 
Motor Neuron Disease
Humberto Foyaca Sibat and Lourdes de Fátima Ibañez Valdés
1. Introduction
Motor neuron disease (MND) represents a wide and heterogeneous expanding 
group of diseases affecting the upper or lower motor neurons, mainly represented 
by amyotrophic lateral sclerosis (ALS), primary lateral sclerosis (PLS), progressive 
muscular atrophy (PMA), and progressive bulbar palsy. ALS is a disease of motor 
neuron degeneration in the cerebral hemisphere, brainstem, and spinal cord with a 
fatal prognosis in most of the cases due to a progressive paralysis of the diaphragm 
and other respiratory muscles leading to respiratory dysfunction and failure. 
Another recently recognized hallmark of ALS pathogenesis is vascular pathology 
apart from central nervous system capillary injury and microvascular impairment 
outside of the CNS [1].
2. Comments
Our first chapter is about stem cell therapy as a novel and promising modality 
for the treatment of ALS/MND. Robust safety profiles, low risk to benefit ratio, 
and ease of access make this approach a strong contender in the race against ALS/
MND. Our authors concluded that this procedure is not a curative treatment, but 
a combinatorial approach integrating stem cell therapy, intensive neurorehabilita-
tion, and current pharmacotherapeutic agents (e.g., Riluzole, Lithium, etc.) may be 
the best way forward. This chapter was written early last year (2019), but unfor-
tunately, a prolonged editorial process impeded to publish this information at due 
time. However, we reviewed the medical literature and found that the abovemen-
tioned information has been confirmed recently (March 2020) by other authors [2].
In this book, we discussed about the pathogenic contribution of a subtype of 
aberrant glial phenotype into the progression and output of the neurodegenerative 
disease ALS and concluded that aberrant astrocytes or more generally aberrant 
glial cells are among the most important players in CNS damage causing deleterious 
effects through many potential pathological mechanisms, mostly sustained on their 
exacerbated proliferation together with their unprecedented neurotoxicity suggest 
that controlling these populations seems at least equally important than mainte-
nance or restoration of homeostatic astrocyte functions to achieve CNS protection 
and repair. Another authors also suggest that aberrant glial cells (AbGC) isolated 
from the spinal cords of adult paralytic SOD1G93A rats exhibit highly proliferative 
and neurotoxic properties and may contribute to disease progression [4]. Same 
authors also established that mitochondrial dysfunction and neurotoxicity that can 
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be reduced by dichloroacetate (DCA), a metabolic modulator that has been used in 
humans, show beneficial effects on disease outcome in SOD1G93A mice. They also 
highlight that DCA treatment of AbGC reduced extracellular lactate levels indi-
cating that the main recognized DCA action targets the pyruvate dehydrogenase 
kinase/pyruvate dehydrogenase complex, and the results confirmed that AbGC 
metabolic phenotype is related to their toxicity to MNs and indicated that its modu-
lation can reduce glial mediated pathology in the spinal cord [3]. At this point, it is 
important to emphasize that neuronal cell death is the main pathological feature of 
chronic neurodegenerative diseases (NDs) like ALS. A common hallmark of several 
NDs is the accumulation and aggregation of proteins; such proteins are thought to 
be primarily turned over by autophagy. Therefore, autophagy is considered a critical 
ND-protective pathway, which opens up potential new therapeutic interventions, 
and some authors have been considering the roles of autophagy and its contribution 
to neurodegeneration in neurons and concluded that little is known about the func-
tions and disease contribution of the autophagy machinery in glia cells [4].
The next chapter of this book is related to the structural and functional con-
sequences of the SMA-linked missense mutations of the survival motor neuron 
protein, where the authors deliver a brief update of the structural and functional 
consequences of the missense mutations of this SMA protein. There is another 
before published chapter where the same author investigates how SMA-linked 
mutations of SMN1 lead to structural/functional deficiency of SMN, and a set of 
computational analysis of SMN-related structures was conducted, described, and 
highlighted three residues of SMN (Asp44, Glu134, and Gln136), and the electro-
static basis of how the SMA-linked missense mutations of the three residues cause 
structural/functional deficiency of SMN and also a possibility of SMN’s Lys45 and 
Asp36 acting as two electrostatically stabilizing clips at the SMN-Gemin2 complex 
structure interface [5].
Mutations to the gene encoding superoxide dismutase-1 (SOD1) were the first 
genetic elements discovered that cause motor neuron disease (MND). Around 10 
years back, the unique way to test ALS-related gene was SOD1 sequencing. Based 
on this postulate, we approved to include into this project a novel review about 
the current understanding of ALS-related genes, summarize the worldwide ALS 
distribution feature by frequency of occurrence in different regions, and outline the 
genetic testing consideration, within many advances in the field of ALS genetics. In 
this chapter, the author highlights the recent advances in ALS gene map, genome-
wide association study on ALS, genetic testing, and gene therapy.
Finally, we made a bibliography research about MND and the most recent 
advances on treatment and reviewed the most relevant papers published on the 
first trimester of 2019, but as was before-mentioned, this chapter is going to be 
published more than 1 year later when some of our information is already old-
fashioned. Last year, we reviewed on novel information about edaravone, riluzole 
(already approved by Food and Drug Administration), nusinersen, EH301, 
5Fluoroucil, Tryptophan, RNS60, Rasagiline, Tirasemtiv, Aquaporin, Fasudil, 
and Lunasil. In order to deliver to our reader community, more novel information 
about MND/ALS is important to highlight other procedure that has been proposed 
for treatment such as the multifaceted role of kinases in ALS. The comprehensive 
regulation of kinases, however, a better understanding of the disturbances in the 
kinome network in ALS, is needed to properly target specific kinases in the clinic. 
Different kinases have been recently involved in TDP-43 phosphorylation. Among 
these, protein casein kinase-1 is the first kinase identified to phosphorylate TDP-43 
in vivo, followed by tau tubulin kinase 1 and cell division cycle kinase 7. Currently, it 
is recognized that TDP-43 proteinopathy characterized by truncation, ubiquitina-
tion, hyperphosphorylation, and/or nuclear depletion in neurons is the prominent 
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and common pathological feature of sporadic and familiar ALS [6]. Some authors 
explored the effects of a chronic treatment with the compound IGS-2.7 in the TDP-
43 (A315T) transgenic mouse model and found a significant decrease in the levels of 
phosphorylation of TDP-43 in sporadic ALS lymphoblast, while no differences were 
observed in control group, and they arrived to the following conclusion: prolonged 
treatment with IGS-2.7 prevents the phosphorylation of TDP-43 in vivo in the cord 
of TDP-43 transgenic mice, being this effect associated with an attenuation of 
most of the events that reflect the worsening of the pathological phenotype, then 
the inhibition of CK-1δ with the benzothiazole derivative IGS-2.7 may modulate 
TDP-43 toxicity in vivo by limiting TDP-43 phosphorylation, which could explain 
the benefits obtained with this drug candidate in the preservation of spinal motor 
neurons. Therefore, benzothiazole IGS-2.7 has neuroprotective properties and not 
only decreases TDP-43 phosphorylation in cells derived from ALS patients but also 
corrects the subcellular localization of TDP-43, preventing the abnormal cytosolic 
TDP-43 accumulation in ALS lymphoblasts [6].
For another hand, other authors reported that 185 miRNAs in serum of 
affected patients and controls confirmed a downregulation of miR-335-5p in ALS 
patients [7].
Because we are under obligation to deliver the most recent information about 
MND/ALS therapy to our reader’s community, then we would like to comment 
about clinically used ebselen and related analogues to promote thermal stabil-
ity of A4V SOD1 when binding to Cys111 only [8]. Ebselen is an organoselenium 
compound with activity similar to glutathione peroxidase [9]. Several studies have 
demonstrated the neuroprotective activity of ebselen, possibly via its anti-oxidant 
properties [10, 11]. The capacity of ebselen to decrease mitochondrial cellular toxic-
ity caused by mutant SOD1 confirmed that this compound plays an important role 
in alleviating familial ALS [12].
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